Inhibitors of the heme oxygenase - carbon monoxide system: on the doorstep of the clinic?
Kinobe, RT; Dercho, RA; Nakatsu, K
| HERO ID | 610534 |
|---|---|
| In Press | No |
| Year | 2008 |
| Title | Inhibitors of the heme oxygenase - carbon monoxide system: on the doorstep of the clinic? |
| Authors | Kinobe, RT; Dercho, RA; Nakatsu, K |
| Journal | Canadian Journal of Physiology and Pharmacology |
| Volume | 86 |
| Issue | 9 |
| Page Numbers | 577-599 |
| Abstract | The past decade has seen substantial developments in our understanding of the physiology, pathology, and pharmacology of heme oxygenases (HO), to the point that investigators in the field are beginning to contemplate therapies based on administration of HO agonists or HO inhibitors. A significant amount of our current knowledge is based on the judicious application of metalloporphyrin inhibitors of HO, despite their limitations of selectivity. Recently, imidazole-based compounds have been identified as potent and more selective HO inhibitors. This ‘next generation’ of HO inhibitors offers a number of desirable characteristics, including isozyme selectivity, negligible effects on HO protein expression, and physicochemical properties favourable for in vivo distribution. Some of the applications of HO inhibitors that have been suggested are treatment of hyperbilirubinemia, neurodegenerative disorders, certain types of cancer, and bacterial and fungal infections. In this review, we address various approaches to altering HO activity with a focus on the potential applications of second-generation inhibitors of HO. Au cours de la dernière décennie, de nombreuses études ont contribué àenrichir notre compréhension de la physiologie, de la pathologie et de la pharmacologie des hèmes oxygénases (HO) ; on envisage d’ailleurs des traitements basés sur l’administration d’agonistes de l’HO et d’inhibiteurs de l’HO. Notre connaissance actuelle est basée principalement sur l’application judicieuse des métalloporphyrines, inhibiteurs de l’HO car elles posent des problèmes de sélectivité. Récemment, on a identifié des composés àbase d’imidazole dotés d’un pouvoir plus sélectif concernant les inhibiteurs de l’HO. La prochaine génération d’inhibiteurs de l’HO pré... [ABSTRACT FROM AUTHOR] Copyright of Canadian Journal of Physiology & Pharmacology is the property of NRC Research Press and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts) |
| Doi | 10.1139/Y08-066 |
| Pmid | 18758507 |
| Wosid | WOS:000259795500001 |
| Is Certified Translation | No |
| Dupe Override | No |
| Comments | Source: Web of Science WOS:000259795500001 |
| Is Public | Yes |
| Keyword | HEME oxygenase; CARBON monoxide; IMIDAZOLES; HYPERBILIRUBINEMIA; NERVOUS system -- Degeneration; MYCOSES; heme oxygenases; imidazole-based inhibitors and clinical applications; metalloporphyrins |
| Is Qa | No |